November 3, 2009 4:27 PM
- Text
J&J Layoffs: The Jobs That Are Safest and Those That Aren't
(MoneyWatch) Johnson & Johnson (JNJ) anounced it would lay off up to 8,100 of its workers today. But whose jobs are safest and whose are in most jeopardy? A look at the recent performance of some of J&J's divisions and products will potentially tell you where J&J might spare the ax and where, conversely, the pink slips are more likely to fall like snow (see below).
J&J gave this explanation for the job cuts. It wants to achieve:
(Source: SEC filings.)
As you can see, J&J gets $3.16 in revenue for every dollar it spends to make it, and of that about $2.23 is gross profit. It was trending up until recently, when it seems to have reached a plateau. In Q3 2009, J&J saw revenues fall 5.3 percent to $15 billion and net income rise 1.1 percent to $3.3 billion.
But a look at the individual products and divisions that are faring best and worst gives a potential guide to whose jobs may be in danger and whose aren't. The chart gives the division or product, followed by the percentage sales growth. Obviously, it is more likely that J&J will ax jobs in the poorer-performing business units than in the growing ones.
J&J gave this explanation for the job cuts. It wants to achieve:
... cost savings of $1.4-$1.7 billion when fully implemented in 2011, with $800-$900 million expected to be achieved in 2010.
The company estimates that position eliminations will be in a range of 6-7 percent of its global workforceAs J&J has about 117,000 workers, up to 8,190 may be laid off. The overall reason why the company is doing this can be found in this graph. It shows the amount J&J earns back in revenue and gross profit for every dollar it spends on sales, admin and marketing -- the bulk of the company's daily expenses.
(Source: SEC filings.)
As you can see, J&J gets $3.16 in revenue for every dollar it spends to make it, and of that about $2.23 is gross profit. It was trending up until recently, when it seems to have reached a plateau. In Q3 2009, J&J saw revenues fall 5.3 percent to $15 billion and net income rise 1.1 percent to $3.3 billion.But a look at the individual products and divisions that are faring best and worst gives a potential guide to whose jobs may be in danger and whose aren't. The chart gives the division or product, followed by the percentage sales growth. Obviously, it is more likely that J&J will ax jobs in the poorer-performing business units than in the growing ones.
- Safest Jobs?
- U.S. Skin Care +3.4%
- International Wound Care +11.6%
- Remicade/Simponi +5.0%
- Velcade +21.6%
- Prezista +91%
- U.S. Concerta + 7.9%
- Jobs in most jeopardy?
- U.S. Baby Care -10.5%
- U.S. Women's health - 13.4%
- Duragesic -20.5%
- Procrit -12.4%
- Topamax - 76%
- Risperdal -40%
Latest Now in MoneyWatch
- Insurers respond cautiously to contraceptive plan
- Judge: Legally, breastfeeding not related to pregnancy
- Budget deficit drops to $27 billion in January
- Why the Powerball Jackpot is part of my investment strategy
- Is the new VW Beetle diesel worth the money?
- Consumer sentiment highlights risks to recovery
- Valentine blues? 10 best cities to be single
- December trade deficit widens to $48.8 billion
- Alcatel-Lucent returns to profit in 2011
- 6 things never to say in a performance review
- $26B mortgage deal: Who gets the money?
- Friendly's CEO steps down
- Quarterly loss hits $3.3B at Postal Service
- Greeks rail against cuts as EU demands more
- 6 things you should never share on Facebook
- Make moves now to increase financial aid
- Valentine's Day: 9 places to save
Latest CBS News Headlines
on Facebook Most Discussed Stories
on CBS News
- Wade scores 26, Bosh 24; Heat beat Wizards 106-89
- Great February getaways, for less
- Tyreke Evans leads Kings past Thunder
- Tyreke Evans leads Kings past Thunder
on Facebook Most Discussed Stories
on CBS News
